BioArctic Enters “Growth Era” on Record 2025 and Expanding Leqembi Reach

An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available.

BioArctic reported a transformative 2025, driven by rapid global expansion of Alzheimer’s therapy Leqembi through partner Eisai and record financial results that doubled its cash position. Leqembi, including the new subcutaneous Leqembi Iqlik version, gained approvals or launches across major markets such as the U.S., Japan, China, Brazil, Canada, the U.K. and others, with priority reviews underway in key territories and growing patient uptake despite pricing and inventory headwinds.

Fourth-quarter net revenues rose sharply, supported by a 31 percent increase in Leqembi royalty income and new income from a Novartis agreement, though quarterly profit was slightly negative while cash flow from operations was strong. The company’s board proposed a dividend for 2025, and management emphasized that the strengthened balance sheet will support an expanded R&D push, including new projects in Huntington’s and Parkinson’s disease, candidate nominations in ALS and Parkinson-related disorders, and continued investment in its BrainTransporter platform to attract additional strategic partnerships.

BioArctic advanced multiple pipeline assets, with Phase 2a trials for exidavnemab in Parkinson’s disease and multiple system atrophy progressing toward completion in 2026 and planning already underway for Phase 2b. Management framed 2025 as the beginning of a “growth era,” in which robust Leqembi royalties, broader market penetration and a deeper neurology pipeline are expected to underpin the company’s long-term growth and enhance its standing as a key innovator in neurodegenerative disease treatments.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

More about BioArctic AB Class B

BioArctic AB is a Swedish biopharmaceutical company focused on neurodegenerative diseases, developing antibody-based treatments and brain transport technologies primarily for Alzheimer’s, Parkinson’s, ALS, and related disorders. The company generates revenue through partnerships with global pharma players, notably Eisai for Alzheimer’s drug Leqembi, and is expanding its pipeline and collaborations to strengthen its position in CNS therapeutics.

Average Trading Volume: 208,665

Technical Sentiment Signal: Buy

Current Market Cap: SEK28.56B

See more data about BIOA.B stock on TipRanks’ Stock Analysis page.